Fragment-based drug design of novel pyranopyridones as cell active and orally bioavailable tankyrase inhibitors

ACS Medicinal Chemistry Letters

Volumn 6, Issue 9, 2015, Pages 1019-1024

  De Vicente, Javier ^a   Tivitmahaisoon, Parcharee ^a   Berry, Pamela ^a   Bolin, David R ^a   Carvajal, Daisy ^a   He, Wei ^a   Huang, Kuo Sen ^a   Janson, Cheryl ^a   Liang, Lena ^a   Lukacs, Christine ^a   Petersen, Ann ^a   Qian, Hong ^a   Yi, Lin ^a   Zhuang, Yong ^a   Hermann, Johannes C ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

axin; fragment based drug design; oncology; structure based drug design; Tankyrase inhibitor; Wnt

Indexed keywords

PYRANOPYRIDONE DERIVATIVE; TANKYRASE INHIBITOR; UNCLASSIFIED DRUG; WNT PROTEIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CELL ASSAY; DRUG BIOAVAILABILITY; DRUG DESIGN; HYDROGEN BOND; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUME OF DISTRIBUTION; VOLUME OF DISTRIBUTION AT STEADY-STATE; WNT SIGNALING PATHWAY;

EID: 84941558639     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.5b00251     Document Type: Article

References (28)

1. Clevers, H. Wnt/β-Catenin Signaling in Development and Disease Cell 2006, 127 (3) 469-480 10.1016/j.cell.2006.10.018
2. Lee, E.; Salic, A.; Krüger, R.; Heinrich, R.; Kirschner, M. W. The Roles of APC and Axin Derived from Experimental and Theoretical Analysis of the Wnt Pathway PLoS Biol. 2003, 1 (1) e10 10.1371/journal.pbio.0000010
3. Behrens, J.; Jerchow, B.-A.; Würtele, M.; Grimm, J.; Asbrand, C.; Wirtz, R.; Kühl, M.; Wedlich, D.; Birchmeier, W. Functional Interaction of an Axin Homolog, Conductin, with β-Catenin, APC, and GSK3β Science 1998, 280 (5363) 596-599 10.1126/science.280.5363.596
4. Klaus, A.; Birchmeier, W. Wnt signalling and its impact on development and cancer Nat. Rev. Cancer 2008, 8 (5) 387-398 10.1038/nrc2389
5. Barker, N.; Clevers, H. Mining the Wnt pathway for cancer therapeutics Nat. Rev. Drug Discovery 2006, 5 (12) 997-1014 10.1038/nrd2154
6. Reya, T.; Clevers, H. Wnt signalling in stem cells and cancer Nature 2005, 434 (7035) 843-850 10.1038/nature03319
7. Mori, Y.; Nagse, H.; Ando, H.; Horii, A.; Ichii, S.; Nakatsuru, S.; Aoki, T.; Miki, Y.; Mori, T.; Nakamura, Y. Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene Hum. Mol. Genet. 1992, 1 (4) 229-233 10.1093/hmg/1.4.229
8. Powell, S. M.; Zilz, N.; Beazer-Barclay, Y.; Bryan, T. M.; Hamilton, S. R.; Thibodeau, S. N.; Vogelstein, B.; Kinzler, K. W. APC mutations occur early during colorectal tumorigenesis Nature 1992, 359 (6392) 235-237 10.1038/359235a0
9. Kinzler, K. W.; Vogelstein, B. Lessons from hereditary colorectal cancer Cell 1996, 87 (2) 159-170 10.1016/S0092-8674(00)81333-1
10. Verkaar, F.; Zaman, G. J. R. New avenues to target Wnt/β-catenin signaling Drug Discovery Today 2011, 16 (1-2) 35-41 10.1016/j.drudis.2010.11.007
11. MacDonald, B. T.; Tamai, K.; He, X. Wnt/beta-catenin signaling: components, mechanisms, and diseases Dev. Cell 2009, 17 (1) 9-26 10.1016/j.devcel.2009.06.016
12. MacDonald, B. T.; Tamai, K.; He, X. Wnt/beta-catenin signaling: components, mechanisms, and diseases Dev. Cell 2009, 17 (1) 9-26 10.1016/j.devcel.2009.06.016
13. Dihlmann, S.; von Knebel Doeberitz, M. Wnt/β-catenin-pathway as a molecular target for future anti-cancer therapeutics Int. J. Cancer 2005, 113 (4) 515-524 10.1002/ijc.20609
14. Leung, J. Y.; Kolligs, F. T.; Wu, R.; Zhai, Y.; Kuick, R.; Hanash, S.; Cho, K. R.; Fearon, E. R. Activation of AXIN2 Expression by β-Catenin-T Cell Factor J. Biol. Chem. 2002, 277 (24) 21657-21665 10.1074/jbc.M200139200
15. Huang, S.-M. A.; Mishina, Y. M.; Liu, S.; Cheung, A.; Stegmeier, F.; Michaud, G. A.; Charlat, O.; Wiellette, E.; Zhang, Y.; Wiessner, S.; Hild, M.; Shi, X.; Wilson, C. J.; Mickanin, C.; Myer, V.; Fazal, A.; Tomlinson, R.; Serluca, F.; Shao, W.; Cheng, H.; Shultz, M.; Rau, C.; Schirle, M.; Schlegl, J.; Ghidelli, S.; Fawell, S.; Lu, C.; Curtis, D.; Kirschner, M. W.; Lengauer, C.; Finan, P. M.; Tallarico, J. A.; Bouwmeester, T.; Porter, J. A.; Bauer, A.; Cong, F. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling Nature 2009, 461 (7264) 614-620 10.1038/nature08356
16. Chen, B.; Dodge, M. E.; Tang, W.; Lu, J.; Ma, Z.; Fan, C.-W.; Wei, S.; Hao, W.; Kilgore, J.; Williams, N. S.; Roth, M. G.; Amatruda, J. F.; Chen, C.; Lum, L. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer Nat. Chem. Biol. 2009, 5 (2) 100-107 10.1038/nchembio.137
17. Waaler, J.; Machon, O.; Tumova, L.; Dinh, H.; Korinek, V.; Wilson, S. R.; Paulsen, J. E.; Pedersen, N. M.; Eide, T. J.; Machonova, O.; Gradl, D.; Voronkov, A.; von Kries, J. P.; Krauss, S. A Novel Tankyrase Inhibitor Decreases Canonical Wnt Signaling in Colon Carcinoma Cells and Reduces Tumor Growth in Conditional APC Mutant Mice Cancer Res. 2012, 72 (11) 2822-2832 10.1158/0008-5472.CAN-11-3336
18. Voronkov, A.; Holsworth, D. D.; Waaler, J.; Wilson, S. R.; Ekblad, B.; Perdreau-Dahl, H.; Dinh, H.; Drewes, G.; Hopf, C.; Morth, J. P.; Krauss, S. Structural Basis and SAR for G007-LK, a Lead Stage 1,2,4-Triazole Based Specific Tankyrase 1/2 Inhibitor J. Med. Chem. 2013, 56, 3012-3023 10.1021/jm4000566
19. Shultz, M. D.; Cheung, A. K.; Kirby, C. A.; Firestone, B.; Fan, J.; Chen, C. H.-T.; Chen, Z.; Chin, D. N.; DiPietro, L.; Fazal, A.; Feng, Y.; Fortin, P. D.; Gould, T.; Lagu, B.; Lei, H.; Lenoir, F.; Majumdar, D.; Ochala, E.; Palermo, M. G.; Pham, L.; Pu, M.; Smith, T.; Stams, T.; Tomlinson, R. C.; Toure, B. B.; Visser, M.; Wang, R. M.; Waters, N. J.; Shao, W. Identification of NVP-TNKS656: The Use of Structure-Efficiency Relationships To Generate a Highly Potent, Selective, and Orally Active Tankyrase Inhibitor J. Med. Chem. 2013, 56, 6495-6511 10.1021/jm400807n
20. Larsson, E. A.; Jansson, A.; Ng, F. M.; Then, S. W.; Panicker, R.; Liu, B.; Sangthongpitag, K.; Pendharkar, V.; Tai, S. J.; Hill, J.; Dan, C.; Ho, S. Y.; Cheong, W. W.; Poulsen, A.; Blanchard, S.; Lin, G. R.; Alam, J.; Keller, T. H.; Nordlund, P. Fragment-based ligand design of novel potent inhibitors of tankyrases J. Med. Chem. 2013, 56, 4497-4508 10.1021/jm400211f
21. Bregman, H.; Chakka, N.; Guzman-Perez, A.; Gunaydin, H.; Gu, Y.; Huang, X.; Berry, V.; Liu, J.; Teffera, Y.; Huang, L.; Egge, B.; Mullady, E. L.; Schneider, S.; Andrews, P. S.; Mishra, A.; Newcomb, J.; Serafino, R.; Strathdee, C. A.; Turci, S. M.; Wilson, C.; DiMauro, E. F. Discovery of Novel, Induced-Pocket Binding Oxazolidinones as Potent, Selective, and Orally Bioavailable Tankyrase Inhibitors J. Med. Chem. 2013, 56, 4320-4342 10.1021/jm4000038
22. Johannes, J. W.; Almeida, L.; Barlaam, B.; Boriack-Sjodin, P. A.; Casella, R.; Croft, R. O.; Dishington, A. P.; Gingipalli, L.; Gu, C.; Hawkins, J. L.; Holmes, J. L.; Howard, T.; Huang, J.; Ioannidis, S.; Kazmirski, S.; Lamb, M. L.; McGuire, T. M.; Moore, J. E.; Ogg, D.; Patel, A.; Pike, K. G.; Pontz, T.; Robb, G. R.; Su, N.; Wang, H.; Wu, X.; Zhang, H.-J.; Zhang, Y.; Zheng, X.; Wang, T. Pyrimidinone Nicotinamide Mimetics as Selective Tankyrase and Wnt Pathway Inhibitors Suitable for in Vivo Pharmacology ACS Med. Chem. Lett. 2015, 6, 254-259 10.1021/ml5003663
23. Nathubhai, A.; Wood, P. J.; Lloyd, M. D.; Thompson, A. S.; Threadgill, M. D. Design and Discovery of 2-Arylquinazolin-4-ones as Potent and Selective Inhibitors of Tankyrases ACS Med. Chem. Lett. 2013, 4, 1173-1177 10.1021/ml400260b
24. Voronkov, A.; Holsworth, D. D.; Waaler, J.; Wilson, S. R.; Ekblad, B.; Perdreau-Dahl, H.; Dinh, H.; Drewes, G.; Hopf, C.; Morth, J. P.; Krauss, S. Structural Basis and SAR for G007-LK, a Lead Stage 1,2,4-Triazole Based Specific Tankyrase 1/2 Inhibitor J. Med. Chem. 2013, 56, 3012-3023 10.1021/jm4000566
25. Karlberg, T.; Markova, N.; Johansson, I.; Hammarström, M.; Schütz, P.; Weigelt, J.; Schüler, H. Structural Basis for the Interaction between Tankyrase-2 and a Potent Wnt-Signaling Inhibitor J. Med. Chem. 2010, 53 (14) 5352-5355 10.1021/jm100249w
26. Narwal, M.; Venkannagari, H.; Lehtio, L. Structural Basis of Selective Inhibition of Human Tankyrases J. Med. Chem. 2012, 55, 1360-1367 10.1021/jm201510p
27. The PyMOL Molecular Graphics System, version 1.5.0.4; Schrödinger, LLC: New York.
28. Alsenz, J.; Kansy, M. High throughput solubility measurement in drug discovery and development Adv. Drug Delivery Rev. 2007, 59 (7) 546-567 10.1016/j.addr.2007.05.007